Healthcare Innovations: WeightWatchers' Amazon Deal and Glaukos' FDA Approval

WeightWatchers partners with Amazon to streamline delivery of weight-loss drugs, boosting its stock by 9%. Meanwhile, Glaukos receives FDA approval for a new eye therapy offering a less painful treatment option, increasing its shares by 2.6%. These developments highlight significant advancements in health and telemedicine.

WeightWatchers teams up with Amazon to offer seamless delivery of weight-loss drugs, leveraging Amazon's pharmacy services. This strategic partnership is expected to benefit WeightWatchers financially as it simplifies medication fulfillment for customers, with the company's shares surging by 9% in response.

In other health news, Glaukos Corp has received FDA approval for a new eye therapy that provides a less painful treatment alternative for a progressive eye condition. This approval has positively impacted the company's market performance, with shares seeing a 2.6% increase in premarket trading.

These advancements underscore the ongoing transformations within the healthcare industry, emphasizing the growing role of telemedicine and innovative treatments in enhancing patient care.

(With inputs from agencies.)